Urine hormone tracking may reveal hidden uterine cancer clues

NCT ID NCT07581288

First seen May 18, 2026 · Last updated Jun 20, 2026 · Updated 10 times

Summary

This study will ask 50 people with abnormal uterine bleeding to collect daily urine samples and track their bleeding for one month. Researchers will use a home monitor to measure hormone levels and see if patterns can predict uterine cancer or precancerous changes. The goal is to find a simple, non-invasive way to catch cancer risks earlier.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UTERINE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Vancouver General Hospital Research Pavillion

    Vancouver, British Columbia, V5Z 1N1, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a simple urine test to help identify who is at higher risk for uterine cancer, enabling earlier detection.

What could go wrong

This is a small, early observational study (50 people) that only measures hormones and bleeding—it does not test a treatment or directly prove cancer detection. Many such biomarker studies fail to translate into a usable test.

Conditions

The condition(s) this trial relates to.

Endometrial Hyperplasia endometrium neoplasm Metrorrhagia uterine cancer Uterine Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.